Stem Cell Educator Therapy a Diabetes I.
Profesor Yong Zhao z University of Chicago přijel do ČR a setkal se s předsedou Diabetologické společnosti ČSL JEP, panem Prof. MUDr.Michalem Andělem, děkanem III. LF, které proběhlo ve Fakultní nemocnici Královské Vinohrady a také se zástupci SUKL.
Primecell launches new representative office in New York
In line with its business strategy and to enhance the attractiveness of the Czech Republic in the global field of research and development of Advanced Therapy, PrimeCell Inc. is expanding its business activities in the US market. As of November 2012, PrimeCell has a new representative office in New York, US.
Therapeutic programmes based on human body cells on growth
One of the expected upcoming partners of Primecell, American-based Athersys, which is one of the worldwide leaders and dominant players in the field of regenerative medicine, recently announced it was named for the second year in Deloitte’s Technology Fast 500™.
Interview: Czech PrimeCell sees potential in Advanced Therapy Medicinal Products
Central Europe Pharma News talks to Mr Michal Zahradnicek, Chairman of the Supervisory Board at PrimeCell, a Czech company focused on Advanced Therapy Medicinal Products (ATMPs), about the development prospects for its products in the Czech Republic and Central and Eastern Europe.
For the full interview please click here.
PrimeCell to attend the London Regenerative Medicine Conference
PrimeCell, one of the European leaders in the area of Regenerative Medicine, is pleased to announce that is it to join the industry world leaders at the 10th Commercial Translation of Regenerative Medicine Conference in London, UK, this November.
National Tissue Centre brings further benefits to the umbilical cord blood banking
Continuously increasing the benefits of private cord blood banking, the National Tissue Centre, one of the subsidiaries of PrimeCell, has recently obtained a permission to transfer stored umbilical cord blood abroad.
National Tissue Centre to participate at the Tissue facilities conference 2012
PrimeCell is pleased to announce that one of its subsidiaries, the National Tissue Centre, is to participate at IIR conference, namely, Tissue facilities – legislation – inspection – transport – Advanced Therapy, to present its selected activities.
Stem cells attract affluent Czech investors
Stem cell-based medicinal products, that are intended to treat damaged joints and tissues, have been continuously attracting affluent Czech investors. In the National Tissue Centre, PrimeCell has been producing the first tissue medicinal products for orthopaedic use since last year. For the full article published in ihned.cz click here.
National Tissue Centre expands its portfolio of hospitals which collect umbilical cord blood for autologous use
National Centre for Tissue Inc., one of the subsidiaries of PrimeCell Inc. has officially expanded its portfolio of co-operating hospitals in the Czech Republic for the collection of umbilical cord blood, a unique source of stem cells, which has the ability to treat a wide spectrum of diseases.
National Tissue Centre announces changes within the members of the Supervisory Board
National Tissue Centre Inc., one of the companies of Primecell Inc., announces that one of the members of the Supervisory Board, Pavel Březovký, MD has officially resigned, as a result of his successful election to the new position as the director of the State institute for drug control, Czech Republic.
PrimeCell to participate at the World Stem Cells Congress
PrimeCell is pleased to announce its participation at The 2012 World Stem Cells and Regenerative Medicine Congress, the region´s largest conference within the industry, which is scheduled to take place on May 21 – 23, 2012 in London, UK, at Victoria Park Plaza.
PrimeCell extends its technology portfolio
PrimeCell, emerging regenerative medicine firm in the Czech Republic, is pleased to announce that TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications is installing a system, namely, CellBase CT™ to improve reproducibility and affordability of its autologous cell therapies.